Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration
Authors
Xihong Zhang
Min Lin
Kenneth L. van Golen
Kiyoko Yoshioka
Kazuyuki Itoh
Douglas Yee
Publication date
01-09-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-4626-8

Other articles of this Issue 2/2005

Breast Cancer Research and Treatment 2/2005 Go to the issue

Report

Incidence of Male Breast Cancer in California, 1988–2000: Racial/Ethnic Variation in 1759 Men

Report

Inhibition of Either Phosphatidylinositol 3-kinase/Akt or the Mitogen/Extracellular-regulated Kinase, MEK/ERK, Signaling Pathways Suppress Growth of Breast Cancer Cell Lines, but MEK/ERK Signaling is Critical for Cell Survival

Report

Evidence for a Tumour Suppressive Function of APRG1 in Breast Cancer

Report

Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?

Report

The role of X-linked genes in breast cancer

Clinical trial

Timely Withdrawal of G-CSF Reduces the Occurrence of Thrombocytopenia During Dose-dense Chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits